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IL-6 has been investigated under numerous designations by several laboratories
independently since 1980. Its multiple biological activities were identified through
these efforts (reviewedin reference 1). IL-6was first describedasa secretoryproduct
of fibroblasts after induction for IFN-0, and was therefore designated IFN-(32 (2,
3) and 26-kD protein (4). Other investigators later identified a factor involved in
terminal B cell differentiation synthesized by a virus-transformed T cell line (5).
This factor stimulated Ig synthesis in activated B cells andwascalled B celldifferen-
tiation factor/B cell stimulatory factor 2 (BCDF/BSF2)t (5). At the same time, a
monocyte- and fibroblast-derived factor required forthe growth ofB cellhybridoma
lineswas described anddesignated ashybridoma/plasmocytoma growth factor (HPGF)
(6-8).
After IFN-a2, 26-kDprotein, BSF2 and HPGFwere each cloned by recombinant
technology (3, 9-13), it became clearthat they were in fact identical(14-17). Finally,
hepatocyte stimulating factor, a monocyte-derived product thatinduces the hepatic
acute phase response, was alsodiscovered to be identical to IFN-(32/ BSF2 (18). To
unifythelarge collection ofnames for the same molecule, the designation IL-6 was
proposed (19, 20) and agreed upon (21).
IL-6 is synthesized under inflammatory conditions primarilyin peripheral blood
monocytes (6, 22-24), endothelial cells(25-27), and fibroblasts(2-4, 8, 10, 12, 28-34).
Under certain nonphysiological stimulatory conditions (e.g., leukemia virus trans-
formation or stimulation with phorbol esters), T cells have also been reported to
secrete IL-6 (5, 11, 20, 24). Two reports described synthesis in stimulated B cells
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(24, 35). Furthermore, a large number of tumor cells have been found to secrete
IL-6 (20, 28, 32, 36).
The main physiological functions of IL-6 are the differentiation of activated B
cellsto terminally maturated, Ig-secreting plasma cells(5, 11, 37, 38) and the induc-
tion of the hepatic acute phase response (18, 39-47). The latter is characterized by
increased expression of acute phase proteins, such as C-reactive protein (CRP) and
decreased synthesis ofalbumin. Additionally, IL-6 has been shown to play an acces-
sory role in T cell activation (48, 49) and induction of hematopoiesis (50-52).
Although a large body of information has emerged on IL-6, the interaction of
this molecule with its target cells is still poorly understood. Recently, an IL-6-R has
been cloned (53). It is now possible to study the tissue distribution of this receptor
and the regulation of its expression in order to gain a better understanding of the
role of IL-6 within the network of inflammatory mediators. Previously, expression
of IL-6-R mRNA has only been reported for nonphysiological or transformed cell
lines (53). A recent study in the rat showed that 80 % of intravenously administered,
radiolabeled, human rIL-6 binds to hepatocyte membranes (54). This suggests the
presence of an IL-6-R on these cells.
In this communication we report on the expression ofthe IL-6-R in normal human
blood monocytes. It is shownhow IL-6-R expression is regulated in these cells, which
are known to be potent IL-6 producers. By comparing IL-6-R expression in human
monocytes and human hepatocytes, we will demonstrate that the IL-6-R is subjected
to tissue-specific regulation.
Materials and Methods
Endotoxin, Cytokines, and cDNA Probes.
￿
Endotoxin derived from Salmonella abortus equi was
a generous gift of C. Galanos, Max-Planck-Institut fur Immunbiologie (Freiburg, FRG).
Human rIL-1# (5 x 10' U/mg LAY; purity 98.6%) was a generous gift of Biogen (Geneva,
Switzerland). Human rIL-6 used in the experiments was either IL-6/BSF-2 (5 x 103 U/kg)
or IL-6/HPGF (106 U/14g) (13), the latter beinga generous gift of L. Aarden (Central Labo-
ratory ofthe Netherlands Red Cross, Amsterdam). We compared IL-6/BSF2 and IL-6/HPGF
with respect to activity in the B9 hybridoma cell assay and found 1 U BSF2 to be equivalent
to -200 U HPGF. The endotoxin content of all cytokines was <0.1 ng/ml stock solution,
resulting in finalconcentrations ofat least three magnitudes below that. cDNAs used in this
study were a cloned BSF2/IL-6 cDNA (pBSF2-38.1) (11) and a cDNA encoding human IL-6-
R pBSF2R.236 (53). A cDNA for human a2-macroglobulin was a generous gift ofA. Lund-
wall and L. SottrupJensen (University ofAarhus, Denmark). CRP cDNA and albumin cDNA




Biological activity of IL-6 was measured by its proliferative action on the murine
hybridoma cell line B9 (22; generously provided by L. Aarden, Central Laboratory of the
Netherlands Red Cross). Proliferation was measured by means of a colometric assay (55).
Cells were maintained in Iscove's modified Dulbeccds medium (IMDM) supplemented with
5o7o FCS, 5 x 10-5 M 2-ME, penicillin, streptomycin, and 0.1oyo supernatant of a 24-h cul-
ture of human monocytes stimulated with endotoxin (100 ng/ml). For the assay, cells were
harvested by centrifugation and washed four times in PBS with 5% FCS. 104 cells were
seeded in flat-bottomed microtitre plates (Costar, Cambridge, MA) containing 100 pl of a
serial twofold dilution in IMDM of the material to be tested. After incubation for 4 d, 50
Al of 1 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma Chem-
ical Co., St. Louis, MD) was added to each well. After another 4-h incubation period, the
supernatant was removed and blue form4zan crystals were dissolved in 0.01 N HCI/ethanol.
The absorbance at 570 nm was measured by a multiwell scanning spectrophotometer (TitertekBAUER ET AL.
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multiskan; Flow Laboratories, Inc., McLean, VA). 1 U/ml is defined as the concentration
of IL-6 leading to half-maximal stimulation of the B9 cell line and equals N1 pg/ml IL-6.
Human Monocyte-Macrophage Cultures. Human blood monocytes were isolated and culti-
vated as described (56) with certain modifications (23). Briefly, buffy coat cellsfrom healthy
blood donorswere diluted in PBS and centrifuged over Ficoll-Hypaque to separate mononuclear
cells from granulocytes and red cells. These mononuclear cells were used for FAGS analysis
(as indicated, either directly or after a 24-h cultivation period). For the other experiments,
monocytes were separated from lymphocytes by adherence. 3 x 106 mononuclear cells/ml
RPMI 1640 medium (supplemented with L-glutamine, antibiotics, 5 x 10-5 mol/liter 2-ME,
and vitamins) plus 10% human AB serum were incubated for 60 min in plastic Petri dishes.
The nonadherent cellswere removed by gentle washings with warm (37'C) medium. More
than 90% of the adherent cells were monocytes as revealed by morphology and phenotype
analysis. For in vitromaturation, monocytes were incubated overnight in supplemented RPMI
1640 medium with 10'Yo human AB serum, then removed from the dishes at 4°C by vigorous
pipetting with a viability of 85-90% (as determined by exclusion oftrypan blue) and placed
into rectangular teflon bags (Biofolie 25; Heraeus, Hanau, FRG) at a concentration of 5 x
105 cells/ml in supplemented RPMI 1640 medium containing 10% human AB serum, and
cultured for different times. At days 3 and 5, fresh medium was added to the bags. For the
experiments, macrophages wereharvested from the bags and plated in 1640 RPMI medium
as above. Between 50 and 80 % ofthe cells that had been placed into the bags could be recov-
ered. More than 90% ofthe cells recovered from the bags were subsequently adherent. After
sedimentation, the few remaining nonadherent cells were removed by washing with the
medium, resulting in 100% pure macrophage cultures. These cells were mature by virtue
of strong staining for the maturation-specific surface antigen maxl (56) (not shown). Com-
plete absence of endotoxin has recently been discovered to be crucial for unimpaired and
reliable monocyte-macrophage in vitro maturation (23, 57, 58). Therefore, all media and
sera used were tested for trace amounts ofendotoxins according to Northoffet al. (59). Strict
observation of this requirement resulted in reproducible experiments with cells from different
donors.
RNA Extraction and Northern Analysis.
￿
RNA was extracted according to the protocol of
Chomczynski and Sacchi (60). For Northern blot hybridizations, 20 hg of total RNA was
subjected to electrophoresis on a 1.2 % agarose-formaldehyde gel for 6 h at 100 V and trans-
ferred to nitrocellulose filters (Schleicher & Schuell, Inc., Keene, NH) according to Maniatis
et al. (61). Standardization was done with respect to 28 S and 18 S rRNA as well as by control
hybridizations with a cDNA clone coding for the housekeeping protein glyceraldehyde phos-
phatedehydrogenase (62). Hybridizations were performed for 24 h with s2P-labeled specific
cDNAs (63) using 2 x 106 cpm of labeled probeper milliliter hybridization buffer (6x SSC,
50% formamide, 0.02% Denhardt's solution). Filters were exposed to Kodak XAR5 films
at -70'C. The bands were scanned with a densitometer (E-C Apparatus Corp., St. Peters-
burg, FL).
FluorescentAntibody Detection by FACSAnalysis.
￿
Phycoerythrin (PE)-conjugated murine mAb
Leis-M3, and FITC-conjugated HLe 1 were obtained from Becton Dickinson & Co. (Moun-
tain View, CA). PE- and FITC-conjugated murine IgG2 myeloma proteins (Becton Dick-
inson& Co.) were used as control antibodies. The murine mAb MT18 (class IgG2b) (Hirata,
Y., T. Taga, M. Hibi, N. Nakano, T. Hirano, and T Kishimoto, manuscript submitted for
publication) was used to detect the 80-kD IL-6-R. An unconjugated IgG2 murine anti-DNP
mAb (DHK10.12, kindly provided by J. Unkeless, Mt. Sinai Medical Center, New York)
served as control stain. Fluorescein-conjugated goat anti-mouse Ig was obtained from Cappel
Laboratories (Malvern, PA). Mononuclear cells were separated by Ficoll-Hypaque centrifu-
gation, washed three times in PBS-BSA (I%) with 0.01% sodium azide, and stained as previ-
ously described (64). Cells were fixed in formalin (1%) before FAGS analysis. Staining was
determined by analysis on an Epics C cytofluorograph (Coulter Electronics, Hialeah, FL),
individually gating on the two major cell populations by lateral and forward light scatter:
a Leu-M3'/Hlel' population (predominantly monocytes), and a Leu-M3 -/HLel' popula-
tion (predominantly lymphocytes). At least2,000 cellswere counted per sample. Isotype con-
trolswere performed in parallel for both direct and indirect test antibodies. Results are dis-
played graphically astwo-dimensional logfluorescence, and numerically as percent fluorescence.1540 INTERLEUKIN 6 RECEPTOR EXPRESSION IN HUMAN MONOCYTES
Hepatocyte Cultures.
￿
Primaryhepatocyte cultures were prepared from fetal livers ofhuman
fetuses after legal abortion at 20 wk ofgestation . Thecultivationprocedure hasalreadybeen
described (65) . Hepatocytesused in this study were kept in Hams F 12 medium/2% human
AB serum containing 10-6M dexamethasone, 10'M insulin, and 10-8M glucagone. Abso-
lutely endotoxin-free conditions were provided .
Results
Expression of the IL-6-R was studied in cultured human blood monocytes and
monocyte-derived macrophages . All experiments were carried out at least three times
with monocytesfrom different donors . Representative experiments areshown. Freshly
prepared, unstimulated humanmonocytes expresshigh levels ofIL-6-RmRNA (Fig.
1 A, lanes 1 and 9) . Upon stimulation with endotoxin, IL-6-R mRNA decreased
markedly within 4 h (Fig. 1 A, lane 2) and remained at nearly undetectable levels
for at least 16h (Fig. 1 A, lanes 3and4) . The effect ofendotoxinwasdose dependent,
with only a slight repression at a concentration of0.1 ng/ml and maximal effects
between 10 and 100 ng/ml . Repression of IL-6-R mRNA was specific, as shown by
a concomitant increase of IL-6 mRNA (Fig . 1 B, lanes 1-4), resulting in a reverse
pattern of regulation of the receptor and its ligand in the same cell population .
When unstimulated monocytes were allowed to undergo in vitro maturation into
macrophages, a gradual spontaneous decline of IL-6-R mRNA was observed (Fig .
1 A, lanes 9-12), whereas expression of a2-macroglobulin, serving as a marker of
macrophage maturation (23, 57, 58), increased steadily (Fig . 1 B, lanes 9-12). When
in vitro matured macrophages were treated with endotoxin, no significant changes
in IL-6-R mRNA could be observed (Fig . 1 A, lanes 5-8) . In addition, endotoxin
was unable to induce strong IL-6 expression in mononuclear phagocytes after ter-
minal maturation (Fig . 1 B, lanes 5-8).







rived macrophages. RNA was
extractedfrommonocytes (lanes
1-4) and monocyte-derived
macrophages after 8dof culti-
vation (lanes 5-8) . Cells were ei-
ther unstimulated (lanes 1 and
5) or stimulatedwith 100 ng/ml
LPS for4h (lanes 2and 6), 8 h
(lanes 3 and 7), or 16 h (lanes
4and8) beforeRNAextraction.
In addition, RNA from un-
stimulated cells immediately
after preparation (dl, lane 9), at
day 3 (d3, lane 10), day 5 (d5,
lane 11), andday8 (d8, lane 12)
ofcultivation was analyzed. 20
Wg of total RNA/lane was sub-
jected to 1.2% agarose gel elec-
trophoresis, blotted onto nitro
cellulose membranes, and hybridized with 32p-labeled IL-6-R cDNA (A). The same filters were rehy-
bridized to radiolabeled IL-6 cDNA (B, lanes 1-8),and a2-macroglobulin cDNA (B, lanes 9-12) . The
autoradiographic exposure time was 3 d for A and 15 h for B) .BAUER ET AL.
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ators (for review, see reference 66), which in turn may act back on the monocyte .
We therefore investigated whether substances produced by monocytes upon endo-
toxin treatment could replace its effect on IL-6-R expression . As shown in Fig. 2
A, treatment of freshly prepared human monocytes with human rIL-1 was able to
suppress IL-6-R expression (Fig. 2 A, lanes 1-5), whereas the expression of IL-6
was concomitantly induced(Fig. 2 B, lanes 1-5) . Thetime kinetics ofIL-6-R mRNA
down regulation were comparable with those seen after endotoxin treatment . The
effect of IL-1 was dose dependent, showing only a slight repression with 10 U/ml
and a maximal effect with 100-200 U IL-1/ml . In contrast to monocytes, in vitro
matured macrophages were hardly responsive to IL-1 treatment with respect to both
IL-6-R mRNA and IL-6 mRNA regulation (Fig. 2, A and B, lanes 6-9) .
Like IL-1, human rIL-6 was also able to induce a reduction in IL-6-R mRNA
levels in monocytes. As shown in Fig. 3, treatment of monocytes with 104 U/ml
HPGF (equivalent to 50 U/ml BSF2) inducedamarked decrease in IL-6-R mRNA.
FIGURE 2 .
￿
Effect of IL-1 on IL-6-R andIL-6mRNA levels in monocytes and monocyte-derived
macrophages . RNA was extracted from monocytes (lanes 1-5) and monocyte-derived macro-
phages after 7 d of cultivation (lanes 6-9) . Cells were either unstimulated (lanes 1, 6), or stimu-
lated with 200 U/ml human rIL-1 for 1 h (lane 2), 3 h(lanes3and 7), 6 h (lane 8), 9 h (lanes
4 and 9), or 18 h (lane 5). 20 1Ag of total RNA/lane was subjected to Northern analysis as de-
scribed in the legend of Fig . 1 andhybridized with 32P-labeled IL-6-R cDNA (A) or IL-6 cDNA
(B) . Autoradiographic exposure time was 3 d for A and 1 d forB .
FIGURE 3 .
￿
Regulation of IL-6-RmRNA in monocytes by IL-6 .
RNA was extracted from unstimulated monocytes (lane 1) or cells
after various times ofIL-6 treatment (104 U/ml HPGF): 1 h (lane
2), 3 h (lane 3), 6 h (lane 4), 9 h (lane 5), and 18 h (lane 6) . 20
FIg of total RNA/lane was subjected to Northern analysis as de-
scribed in the legend of Fig. 1 andhybridized to 32P-labeled IL-
6-R cDNA . The filter was autoradiographed for 5 d .1542 INTERLEUKIN 6 RECEPTOR EXPRESSION IN HUMAN MONOCYTES
Slight effects of IL-6 were seen at 103 U/ml HPGF (equivalent to 5 U/ml BSF2) .
Incubation of monocytes with IL-6 did notincrease IL-6 mRNA levels (not shown).
Since the monocyte cultures used in our studies contained some 5-10% lympho-
cytes, we applied FAGS analysis in order to see whetherthe IL-6-RmRNA detected
in ourexperimentscouldbe attributed to themonocytic population . For FACS anal-
ysis, mononuclear cells were examined either immediately after Ficoll centrifuga-
tion (Fig. 4, A-D) or after a 24-h incubation period (Fig. 4, E) . Both lymphocytes
and monocytes are recognized by themAbHLe. ThemAb Leu-M3 is directed against
the monocyte-specificCD14 epitope. The totalmononuclear cell population is shown
in Fig . 4A, and reveals a large granular (monocytes, Leu-M3+/HLe+), anda small,
less granular subpopulation (lymphocytes, Leu-M3-/HLe+) . The surface expres-
sion of IL-6-R was demonstrated on freshly isolated monocytes . 78% of Leu-
M3+/HLel' cells (monocytes) costained with the MT18 mAb (Fig . 4 C), whereas
FIGURE 4 . Detection of the
IL-6-R on monocytes by FACS
analysis using an anti-IL-6-11
mAb (MT18). Freshly isolated
PBMC after Ficoll centrifuga-
tion are shown in a cytogram
gatingofmononuclear cells (A) .
Granulation ofthe cells is indi-
cated by the light scatter (LS) ;
cell size by forward light scatter
(FLS) . Monocytes represent the
larger and more granulated
population shown in A. In C,
cells identified as monocytes
by staining for the monocyte
marker Leu-M3 show costain-
ing with the anti-IL-6-R mAb
MT18 (78% specific fluores-
cence), whereas control im-
munofluorescence with isotype
(IgG2b)PE-andFITC-labeled
antibodies revealed <3 .5% and
<4.5% fluorescence, respec-
tively. In D, HLel' cells
identified aslymphocytes bythe
absence of Leu-M3 staining
show only weak staining (9%
specific fluorescence) with the
MT18 anti-IL-6-R antibody .
Mononuclear cellscultivated for
24 h (day 2 ofculture)were ana-
lyzed in E. LeuM3' cells
(monocytes) show markedly di-
minished staining with the
MT18 anti-IL-6-R antibody
(9% specific fluorescence) as
compared with C.BAUER ET AL .
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only 9% of Leu-M3 -/HLel + cells (lymphocytes) revealed MT18 surface staining
(Fig . 4D) . Afterincubation in endotoxin-free culturemedium for24 h, surface MT18
immunofluorescence for Leu-M3 +/HLe1+ cells (monocytes) dropped to only 9%
(Fig. 4E), reflecting the observed decrease ofIL-6-R mRNA along in vitro matura-
tion. These data were confirmed when IL-6-R mRNA was demonstrated in mono-
cyte andlymphocyte populations afterfurther purification (Fig. 5) . IL-6-R mRNA
signals in the lymphocyte preparation were several times weaker (as related to total
cellular RNA) and could not be regulated by endotoxin .
Glucocorticoids are knownto influencemany inflammatory responses . We there-
fore examined the effect of glucocorticoid treatment on IL-6-R mRNA expression
in monocytes (Fig . 6) . Dexamethasonecaused atransient and marked drop of IL-6-R
mRNA within 3 h . After 7 h, mRNA levels increased slightly but were still below
unstimulated control levels .
In contrast to monocytes, IL-6-R mRNA in hepatocytes is stimulated both by
IL-1 and by IL-6 (Fig. 7 A) . Nearly no IL-6-R mRNA can be detected in unstimu-
lated primary hepatocytes . However, the presence of an intact IL-6-R molecule on
FIGURE 5 .
￿
Comparison ofIL-6-RmRNA levels in monocyte-enriched
and lymphocyte-enriched cultures. RNA was extracted from unstimu-
lated monocytes after repeated washing steps during 24 h of their initial
adherence to plastic, resulting in further removal of lymphocytes (lane
1) . These cells were therefore at day 2 in culture when harvested. Nonad-
herentmononuclear cellsofthe first adherence stepwerereplated to plastic
in order to achieve further purification from adhering monocytes . Nonad-
herent cells of the second adherence step represented a lymphocyte-
enriched population from whichRNAwas extracted eitherdirectly (lane
3) or after 6 h of endotoxin stimulation (100 ng/ml) (lane 2). 20 /'g of
total RNA/lane was subjected to Northern analysis as described in the
legend of Fig. 1 and hybridized with 32P-labeled IL-6-R cDNA. Auto-
radiographic exposure time was 5 d .
FIGURE 6 .
￿
Decrease ofmonocyticIL-6-RmRNA levels upon treatment
by dexamethasone . RNAwas extracted from unstimulated monocytes
(lane 1) or from cells after 3 h (lane 2) and 7 h (lane 3) of treatmentby
dexamethasone (10-7 M) . 20 /~g of total RNA/lane was subjected to
Northern analysis as described in the legend to Fig . 1 and hybridized
with 32P-labeledIL-6-RcDNA . Autoradiographic exposure time was 5 d .1544 INTERLEUKIN 6 RECEPTOR EXPRESSION IN HUMAN MONOCYTES
FIGURE 7 .
￿
Expression of IL-6-R mRNA in human primary hepatocytes . Poly(A) RNA was
prepared from fetal hepatocytes at day 4 in culture, subjected to Northern analysis (2.5 Wg/lane),
and hybridized with radiolabeled IL-6-RcDNA (A), CRP cDNA (B), and albumincDNA (C) .
(A) Lanes 1-3, a time kinetics of IL-6-RmRNA induction by IL-6 compared with unstimulated
cells (A, lane 1), IL-6-R mRNA is induced in cells stimulated with 100 U/ml of BSF2/L-6 for
12 h (lane 2), or 24 h (lane 3) . (A) Lanes 4-6, a concentration kinetics compared with unstimu-
lated cells (lane 4), 24-h stimulation with 10 U/ml of BSF-2/IL-6 (lane 5), or with 100 U/ml of
BSF2/IL-6 (lane 6) . (A) Lane 7, conditions as in lane 6 except that cells were kept in the absence
of glucocorticoids . (A) Lane 8, stimulation for 24 h with 100 U/ml ofIL-10. (B) Lanes 1-5 repre-
sent the same experimental conditions as in A, lanes 4-8 . (C) Lane 1, unstimulated cells ; lane
2, stimulation with 100 U/ml of BSF-2/IL-6 for 24 h.
the membrane of unstimulated hepatocytes was shown by IL-6-dependent induc-
tion ofCRP (Fig . 7 B) . The specificity of this response is shown by concomitant
downregulation ofalbumin (Fig . 7 C) . If glucocorticoids were omitted from thehe-
patocyte culture medium, IL-6-dependent induction of the IL-6-R was slightly less
pronounced, indicating an opposite effect of glucocorticoids on IL-6-R expression
in monocytes and in hepatocytes .
Discussion
In thepast years, muchhasbeen learnedaboutthe pleiotropic biological activities
ofIL-6. Binding studies predicted the presence ofan IL-6-R on restingT cells, acti-
vatedB cells, and a number of cell lines, includinglymphoblastoid cell lines, plasma
cell lines, the histiocytic cell line U937, the promyelocytic line HL60, an astrocy-
toma, and a glioblastoma cell line (67, 68). However, detailed studies of the IL-6
target cells required the characterization of the IL-6-R . Recently, the IL-6-R has
been cloned (53), and antibodies directed against this receptor have been developed
(Y. Hirata, manuscript submitted for publication) . The IL-6-R has been shown to
be a single 80-kD molecule (69) . If the ligand is bound to the 80-kD protein, the
latter associates with a second membrane-bound protein of 130 kD, resulting in the
signal transduction into the cell (69) .
We have shown that unstimulated monocytes of healthy individuals express IL-6-
RmRNA and that these cells carry the 80-kD receptor molecule on their surface .
Upon stimulation with endotoxin, IL-1, or IL-6, the expression of IL-6-R mRNA
is downregulated. These data suggest that the IL-6 secretion by monocytes under
inflammatory conditions is accompaniedbyadecrease oftheirIL-6-RmRNA levels .
Until now, expression of IL-6-R mRNA has only been shown for a number of
leukemic cell lines (53) . It has also been reported that simultaneous expression of
IL-6 and its receptor in plasmocytomas may constitute an autocrine stimulatoryBAUER ET AL.
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loop resultingin uncontrolled proliferation(36, 70). We can nowpresent an example
of IL-6-R expression in a nonproliferating cell type that is known to be a potent
IL-6 producer. However, downregulation of the monocytic IL-6-R at a time when
IL-6 expression is induced mayrepresent aprotective mechanismagainst autocrine
stimulation.
Thephysiological function ofthe monocytic IL-6-R remains to be elucidated. We
found that treatment ofmonocyteswith IL-6 resultsin an inductionofal-antitrypsin
expression, revealing one ofthepossible functions of the monocytic IL-6-R. Induc-
tion of al-antitrypsin in monocytes by IL-6 has recently been confirmed (D. H.
Perlmutter in reference 21). In addition to the regulation of IL-6-dependent genes,
expression of the IL-6-11on monocytes during noninflammatory homeostasis could
indicate that monocytes mayplay arole in bindingtrace amountsofcirculating IL-6.
Downregulation of the IL-6-R upon stimulation is a tissue-specific event. The
differential regulation ofthe IL-6-R in human monocytes andhepatocytesmayshed
some light on an interesting biological mechanism: monocytes could bind IL-6 on
their surface during noninflammatory homeostasis, thereby protecting other target
cells from IL-6 activity. As soon as an inflammatory situation develops, the target
forIL-6 is shifted from the monocyte to thehepatocyte and presumably to activated
lymphocytes.
Summary
IL-6 is a cytokine with pleiotropic biological functions, including induction of
the hepatic acutephase response and differentiationofactivatedBcells into Ig-secreting
plasma cells. We foundthat human peripheral bloodmonocytesexpressthe IL-6-R,
which is undetectable on the large majority oflymphocytes of healthy individuals.
Stimulation of monocytes by endotoxin or IL-1 causes a rapid downregulation of
IL-6-R mRNA levels and a concomitant enhancement of IL-6 mRNA expression.
IL-6 itself was found to suppress the IL-6-R at high concentrations. A gradual de-
crease ofIL-6-R mRNA levels wasobserved along in vitromaturation ofmonocytes
into macrophages. We show that downregulation of IL-6-R mRNA levels by IL-1
and IL-6 is monocyte specific, since IL-6-R expression is stimulated by both IL-1
and IL-6 in cultured human primary hepatocytes. Our data indicate that under
noninflammatoryconditions, monocytesmayplay arole in bindingoftraceamounts
ofcirculating IL-6. Repression of monocytic IL-6-R and stimulation of hepatocytic
IL-6-R synthesismayrepresent a shiftof theIL-6 tissue targets under inflammatory
conditions.
We thank Dr. Barry Drees for critical reading of this manuscript.
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